معرفی
Dr. Yong-Mi Kim is a Professor of Pediatrics and Pathology at the Keck School of Medicine of USC and serves as an Investigator in Hematology, Oncology and Blood and Marrow Transplantation at Children's Hospital Los Angeles (CHLA). Her research focuses on understanding the mechanisms of drug resistance in acute lymphoblastic leukemia, particularly examining the interactions between leukemia cells and their protective bone marrow microenvironment.
Dr. Kim completed her medical education at Heinrich-Heine-University in Duesseldorf, Germany, followed by an internship and residency at Children's Hospital in Duesseldorf. She furthered her training with a fellowship at Harvard University and earned an MPH from Harvard University School of Public Health.
Her research program investigates four key areas: novel imaging studies of drug-resistant leukemia microenvironment, integrin-mediated adhesion of ALL cells, apoptosis regulation through survivin, and self-renewal pathways involving Wnt/beta-catenin signaling. Her lab has pioneered cutting-edge imaging approaches to study drug resistance in real time, moving beyond static histological images.
Analysis of Dr. Kim's recent publications reveals a strong focus on understanding the physical and molecular characteristics of drug-resistant leukemia cells, particularly examining integrin-mediated adhesion, metabolic adaptations, and novel therapeutic approaches targeting these resistance mechanisms. Her work spans from basic mechanistic studies to translational applications.
- NIH R01CA172896
- St. Baldrick's Foundation Scholar
- Hyundai Hope on Wheels Scholar
- V-foundation
- William Lawrence and Blanche Hughes Foundation
- Couples Against Leukemia
- Whittier Foundation
- Nautica
Dr. Kim actively mentors numerous students and researchers including Eun Ji Gang, Stephanie Shishido, Yann Duchartre, Etai Adam, Hye-Na Kim, Sandra Gonzalez, Ki Jun Lee, Samantha Hurwitz, and Heather Ogana. Her collaborative network includes prominent researchers such as Nora Heisterkamp, Michael Kahn, Steve Mittelman, and Scott Fraser. Her laboratory continues to advance understanding of leukemia biology and develop novel therapeutic strategies to overcome drug resistance.
